338 related articles for article (PubMed ID: 19195847)
1. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).
Olivares JM; Rodriguez-Morales A; Diels J; Povey M; Jacobs A; Zhao Z; Lam A; Villalobos Vega JC; Cuéllar JA; de Castro FJ; Quintero CM; Martíin JF; Domínguez P; Ojeda JL; Cortés SS; Cala FI; Marín CG; Castro LM; Duaso MA; Albarracín JR; Vergara GN; Benítez AF; Cleries FM; Pérez-Brian JM; Aragón AB; Navarro JC; Biedma JA; de Pedro RB; González JF; López ME; Moreno HD; López JA; Rodríguez EO; de Hoyos CM; Sacristán MP; Martín MD; Ballesteros EM; Rodríguez PA; Menéndez LF; Rivas RS; del Pino Cuadrado P; Lauffer JC; Solano JJ; Martínez JM; Solano FG; Rodríguez PG; Rodríguez JA; Cano TR; Fortacin MD; Lobeiras JM; Sampedro JM; Bravo AP; Pellicer AF; López MD; Liste JF; Fernández MR; Losada AC; Mendez RV; Romero SA; Blanco JJ; Bonaselt IT; Mahia MC; del Valle EF; Yañez PQ; Camarasa MG; Alonso JA; Mendez GF; Feliz FD; Lamela MA; Piñero MV; Alvarado PF; Gómez IL; Martín PF; Gómez JL; López AG; Jiménez AR; Nafs AE; Barquero NC; Ortiz RF; Noguera JL; Carrasco PR; Muñoz JM; Palma MM; Hortelano CM; Bonome LS; Sevilla JS; Juan JM; Ramos JM; Muñoz JL; Guisasola JE; Vazquez LS; Guerras FC; Nebot FJ; Fernández FJ; Nicolau AL; Subirats RC; Kidias MM; Navarro VF; García BF; del Rosal FM; de Vicente Muñoz T; Ballester JA; Lieb PM; Martel AD; Bea ER; Joaquim IG; Enjuanes FB; Piñol MB; Carbonell EF; Muñoz RM; Giribets CA; Sans LA; Blanco AS; Felipe MA; Muñoz PG; Villanueva AP; Arroyo MB; Borri RC; Fallada SM; Merola MC; Rodon EP; Palmes JR; Martínez EP; Catala JM; Coca AS; Ferrandiz FP; Paya EF; Caballero GI; Bonet AF; Figueras JF; Pagador PM; Garibo MM; Camo VP; Carrillo CS; Valero CP; Rebollo FJ; García Campayo J; Sala Ayma JM; Roig MM; de Uña Mateos MA; Bertolin RG; García AM; Mazo FJ; Velasco JL; Pérez LS; Casado CJ; Barba JJ; Diaz MC; Rubio JP; Mandoli AS; Herrero AU; Martínez AR; Serrano PS; Rodríguez EN; Montesinos JS; Macia JF; Mateos Marcos AM; Soto JV; Dumont MV; Pagan JP; Martínez VB; Santiuste de Pablos M; Delgado CE; Quiles MD; López FJ; Navarro PP; Torres AM; Ingles FJ; Arias-Camison JM; Manzano JC; Peña RV; Guitarte GP; Fontecilla HB; Romero JB; Gil RS; Lozano JM; Adanez LD; Zarranz Herrera-Oria I; Jiménez JP; Vaz FC; García OS; Anton CC; Casula RR; Hernandez MC; Escabias FT; Torresano JR; Pérez-Villamil AH; Estevez L; Figuero MA; Muñoz de Morales A; Calvin JL; Criado MD; Rodríguez VM; Ambrosolio EB; Madera PM; Alfaro GP; Vidal MM; Valtuille AG; Ruiz O; Cabornero GL; Echevarria Martínez de Bujo M; Mallen MJ; Puigros JS; Martorell AL; Forteza AC; Arrebola ER; Rodríguez de la Torre M; Saiz CG; Bardolet I Casas C; Linde ER; De Arce Cordon R; Molina EM; Carazo FJ; Romero JJ; Cano DV; Dorado MS; Velazquez SC; Sánchez AJ; Leon SO; Sánchez KP; Benitez MH; Zugarramurai AI; Contreras MA; De la Varga González M; Marín PB; Robina FG; García MS; Pérez FJ; Bros PC; Gómez AC; de Dios Molina Martín J; Perera JL; Averbach MC; Perera JL; Palancares EG; Gallego de Dios MT; Rojo CF; Iglesias SS; Merino MI; Mestre NP; Urdaniz AP; Sánchez JM; Seco RG; Muñoz JF; Agut MM; Lozano ML; Herguedas FM; Pena AT; García JV; Martínez AV; Sanz Granado OS; Fernández MA; Canseco JM; López PA; Martín MA; Barrio JA; Ubago JG; Bennassar MR; Díez JM; Fleta JL; Fortes FP; López CA; Medina O; Alvarez DF; Roca JM; Valladolid GR; Tavera JA; García-Castrillon Sales JA; Llordes IB; Melgarejo CA; Cañas de la Paz F; Callol VV; García MB; García JB; Leal FJ; Corrales EC; Iglesias ES; Gómez MA; Serrano GG; Chillarón EG; Aguado FJ; Castillo JJ; González AG; Vázquez JG; Peralvarez MB; Diaz MR; Mesa MY; Artiles FJ; Chao MA; Mesa MY; del Rosario Santana P; Escudero MA; Berenguer MM; Llacer JM; Berna JA; Ortiz JB; Pardell LT; Hernández-Alvarez de Sotomayor C; Méndez MR; Garate RC; Múgica BD; González MC; Domingo JP; Navarro CS; Vera GS; Cuquerella MA; Monzo JL; Boada PC; Pérez MF; Parrado EC; Sánchez JJ; Fernández JC;
Eur Psychiatry; 2009 Jun; 24(5):287-96. PubMed ID: 19195847
[TBL] [Abstract][Full Text] [Related]
2. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
Peuskens J; Olivares JM; Pecenak J; Tuma I; Bij de Weg H; Eriksson L; Resseler S; Akhras K; Jacobs A
Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
[TBL] [Abstract][Full Text] [Related]
3. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Rosa F; Schreiner A; Thomas P; Sherif T
Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
[TBL] [Abstract][Full Text] [Related]
5. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.
Olivares JM; Peuskens J; Pecenak J; Resseler S; Jacobs A; Akhras KS;
Curr Med Res Opin; 2009 Sep; 25(9):2197-206. PubMed ID: 19604073
[TBL] [Abstract][Full Text] [Related]
6. Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database.
Lambert T; Emmerson B; Hustig H; Resseler S; Jacobs A; Butcher B;
BMC Psychiatry; 2012 Mar; 12():25. PubMed ID: 22448928
[TBL] [Abstract][Full Text] [Related]
7. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
10. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study.
De la Gándara J; San Molina L; Rubio G; Rodriguez-Morales A; Hidalgo Borrajo R; Burón JA
Expert Rev Neurother; 2009 Oct; 9(10):1463-74. PubMed ID: 19831836
[TBL] [Abstract][Full Text] [Related]
11. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.
Taylor DM; Young CL; Mace S; Patel MX
J Clin Psychiatry; 2004 Aug; 65(8):1076-83. PubMed ID: 15323592
[TBL] [Abstract][Full Text] [Related]
12. Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study.
Chan HW; Huang CY; Feng WJ; Yen YC
Psychiatry Clin Neurosci; 2015 Aug; 69(8):497-503. PubMed ID: 25781185
[TBL] [Abstract][Full Text] [Related]
13. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
14. Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.
Lammers L; Zehm B; Williams R
BMC Psychiatry; 2013 May; 13():155. PubMed ID: 23718192
[TBL] [Abstract][Full Text] [Related]
15. Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
Cañas F; Möller HJ
Expert Opin Drug Saf; 2010 Sep; 9(5):683-97. PubMed ID: 20690885
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
Parellada E; Kouniakis F; Siurkute A; Schreiner A; Don L
Int Clin Psychopharmacol; 2010 May; 25(3):149-54. PubMed ID: 20305567
[TBL] [Abstract][Full Text] [Related]
17. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series.
Se Hyun Kim ; Dong Chung Jung ; Yong Min Ahn ; Yong Sik Kim
J Psychopharmacol; 2010 Jul; 24(7):981-6. PubMed ID: 19942641
[TBL] [Abstract][Full Text] [Related]
18. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
[TBL] [Abstract][Full Text] [Related]
19. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
20. [Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection].
Mori T
Seishin Shinkeigaku Zasshi; 2011; 113(10):977-82. PubMed ID: 22187885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
